Harmony Biosciences (HRMY) to Release Quarterly Earnings on Tuesday

Harmony Biosciences (NASDAQ:HRMY) will be releasing its earnings data before the market opens on Tuesday, October 29th. Analysts expect Harmony Biosciences to post earnings of $0.66 per share for the quarter. Harmony Biosciences has set its FY 2024 guidance at EPS.Investors that wish to register for the company’s conference call can do so using this link.

Harmony Biosciences (NASDAQ:HRMY) last posted its earnings results on Tuesday, August 6th. The company reported $0.20 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.24. The business had revenue of $172.80 million during the quarter, compared to analyst estimates of $172.53 million. Harmony Biosciences had a return on equity of 22.97% and a net margin of 17.53%. The company’s revenue for the quarter was up 28.8% compared to the same quarter last year. During the same quarter last year, the firm earned $0.56 earnings per share. On average, analysts expect Harmony Biosciences to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Harmony Biosciences Trading Up 1.3 %

HRMY opened at $34.50 on Monday. The firm’s 50 day moving average is $36.40 and its 200-day moving average is $32.96. Harmony Biosciences has a 52-week low of $19.03 and a 52-week high of $40.60. The company has a quick ratio of 3.09, a current ratio of 3.13 and a debt-to-equity ratio of 0.32. The firm has a market capitalization of $1.96 billion, a P/E ratio of 17.69, a P/E/G ratio of 0.69 and a beta of 0.73.

Analysts Set New Price Targets

A number of research firms have weighed in on HRMY. Mizuho upped their price objective on shares of Harmony Biosciences from $42.00 to $52.00 and gave the company an “outperform” rating in a research report on Thursday, October 10th. Needham & Company LLC restated a “buy” rating and set a $52.00 price objective on shares of Harmony Biosciences in a report on Wednesday, October 2nd. Raymond James reiterated an “outperform” rating and set a $40.00 target price on shares of Harmony Biosciences in a research note on Thursday, October 10th. Finally, UBS Group began coverage on shares of Harmony Biosciences in a research note on Tuesday, September 10th. They issued a “buy” rating and a $56.00 price target for the company. Two research analysts have rated the stock with a sell rating and six have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $44.38.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.